Janssen reports real-word data on INVOKANA
Johnson & Johnson's Janssen announced Friday real-world evidence showing people with type 2 diabetes initiated on oral INVOKANA 300mg were as likely as matched patients initiated on injectable GLP-1 receptor agonists to achieve the recognized HEDIS standard of blood glucose control of A1C less than 8.0 percent. Patients on INVOKANA were also less likely to discontinue their medication or be prescribed a new antihyperglycemic agent. These findings were presented at the American Association of Clinical Endocrinologists' Annual Scientific & Clinical Congress. Specifically, the analysis showed: Patients with A1C levels of 8.0 percent or greater before starting either therapy had similar A1C levels at each 3-month interval post-index. Time to reach A1C below 8.0 percent was comparable with INVOKANA and GLP-1 RAs (12.4 months vs. 13.1 months). INVOKANA patients were 30 percent less likely to discontinue initial therapy compared to those initiating GLP-1 RAs, with a median time to discontinuation of 12.4 vs. 8.6 months, respectively. INVOKANA patients were 28 percent less likely to be prescribed a new AHA.